Physiol. Genomics Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 29: 128-138, 2007. First published December 19, 2006; doi:10.1152/physiolgenomics.00197.2006
1094-8341/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
29/2/128    most recent
00197.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chateauvieux, S.
Right arrow Articles by Charbord, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chateauvieux, S.
Right arrow Articles by Charbord, P.
Received 6 September 2006; accepted in final form 17 December 2006.
Physiological Genomics 29:128-138 (2007)
1094-8341/07 $8.00 © 2007 American Physiological Society

Molecular profile of mouse stromal mesenchymal stem cells

Sebastien Chateauvieux 1, Jean-Laurent Ichanté 2, Bruno Delorme 1, Vincent Frouin 2, Geneviève Piétu 2, Alain Langonné 1,3, Nathalie Gallay 1, Luc Sensebé 1,3, Michèle T. Martin 2, Kateri A. Moore 4 and Pierre Charbord 1

1 Institut National de la Santé et de la Recherche Médicale, Equipe-ESPRI/EA-3855, Université François Rabelais, Faculté de Médecine, Tours, France
2 Commissariat à l'Energie Atomique, Service de Génomique Fonctionnelle, Evry
3 Etablissement Français du Sang-Centre-Atlantique, Tours, France
4 Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, New Jersey


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
We determined a transcriptional profile specific for clonal stromal mesenchymal stem cells from adult and fetal hematopoietic sites. To identify mesenchymal stem cell-like stromal cell lines, we evaluated the adipocytic, osteoblastic, chondrocytic, and vascular smooth muscle differentiation potential and also the hematopoietic supportive (stromal) capacity of six mouse stromal cell lines from adult bone marrow and day 14.5 fetal liver. We found that two lines were quadripotent and also supported hematopoiesis, BMC9 from bone marrow and AFT024 from fetal liver. We then ascertained the set of genes differentially expressed in the intersection set of AFT024 and BMC9 compared with those expressed in the union set of two negative control lines, 2018 and BFC012 (both from fetal liver); 346 genes were upregulated and 299 downregulated. Using Ingenuity software, we found two major gene networks with highly significant scores. One network contained downregulated genes that are known to be implicated in osteoblastic differentiation, proliferation, or transformation. The other network contained upregulated genes that belonged to two categories, cytoskeletal genes and genes implicated in the transcriptional machinery. The data extend the concept of stromal mesenchymal stem cells to clonal cell populations derived not only from bone marrow but also from fetal liver. The gene networks described should discriminate this cell type from other types of stem cells and help define the stem cell state.

differentiation; hematopoiesis; cytoskeleton; transcription; gene network


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
DURING DEVELOPMENT, HEMATOPOIESIS takes place in sequential sites (reviewed in Ref. 16). It develops during embryonic life within the extraembryonic annex, the yolk sac, and within the intraembryonic region, the aorta-gonad-mesonephros (AGM) region. During fetal life, it proceeds within the liver. From birth onward, bone marrow is the major, if not exclusive, site of hematopoiesis in mammals. Hematopoietic stem cells (HSCs) migrate, via the bloodstream, from one site to the next. As early as the AGM stage, HSCs have acquired their essential properties of self-renewal and multipotentiality, giving rise to all blood lineages. It is in the fetal liver that HSCs show maximal proliferation capacity: only at this stage is amplification of the HSC pool observed.

Cells from the microenvironment provide different niches for hematopoietic cells. In the HSC niche (reviewed in Refs. 1, 24, 30, 48), the stemness, i.e., the balance between self-renewal and commitment, is insured by physical contact between the HSC and a "stromal" cell (i.e., hematopoietic supportive) and its associated extracellular matrix. In the bone marrow, many recent experiments strongly suggest that the stromal component would be an osteoblastic-type cell or a highly specialized microvascular cell (1). In the fetal liver, fewer studies have tried to define the stromal component of the niche. We have suggested (7) that a cell in epithelial-to-mesenchymal transition would constitute such a stromal component; the final adult fates of such a cell would be hepatocytes and sinusoid vascular smooth muscle cells that would no longer possess the stromal capacity.

In all major hematopoietic sites (AGM, fetal liver, and bone marrow), a new type of stem cells has been described: the mesenchymal stem cells (MSCs) (6, 29, 36). MSCs are multipotential cells that differentiate into adipocytes (A), osteoblasts (O), chondrocytes (C), and vascular smooth muscle cells (V) (reviewed in Refs. 5, 13). It has been suggested that MSCs are identical to stromal cells used as feeder layers for long-term cultures of HSCs (37). In this work, we searched for mesenchymal clonal lines with A, O, C, and V differentiation potential and with similar stromal capacity. We found that two lines had such potential, one being from adult bone marrow, BMC9, and the other from the fetal liver, AFT024. We then tried to establish the transcriptomic profile specific for stromal MSCs independent of the hematopoietic site. To this end, we ascertained the set of genes differentially expressed in the intersection set of AFT024 and BMC9 compared with those expressed in the union set of two negative control "non-MSC" lines. This set would account for the quadripotentiality and the stromal potential, i.e., the specific capacity of this particular type of stem cells.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell Lines
Lines used in this work were either 14.5 days postcoitum (dpc) fetal liver lines (AFT024, 2012, 2018, and BFC012) provided by K.A. Moore or bone marrow lines (BMC9 and BMC10) kindly provided by James E. Dennis (Case Western Reserve University, Cleveland, OH). All lines were immortalized using SV-40 large T-antigen. Large temperature-sensitive T-antigen (TSa-58) lines were made by retroviral transduction into the fetal liver stroma and clonally derived; the clonal nature was verified by Southern blot analysis, which detected a single, unique proviral integration locus in the genomic DNA. The bone marrow lines had been obtained from transgenic immortomice generated by embryonic stem (ES) cells transfected with thermosensitive T under the major histocompatibility complex promoter. The lines were developed from isolated clones. Fetal liver cell lines were cultured at 33°C in 5% CO2 in high-glucose DMEM with 10% (vol/vol) screened fetal calf serum (FCS, Hyclone), 0.1% ß-mercaptoethanol, 2 mM L-glutamine, and antibiotics. Bone marrow cell lines were cultured at 33°C in 5% CO2 in {alpha}-MEM with 10% FCS, 100 IU/ml (50 ng/ml) {gamma}-interferon, 2 mM L-glutamine, antibiotics, and antimycotics.

Differentiation Studies
Osteoblastic differentiation was induced by culture in DMEM (high glucose) medium with 10% FCS, 0.1 µM dexamethasone, 2 mM ß-glycerophosphate, and 150 µM ascorbate-2-phosphate. Cells were seeded at 10,000 cells/cm2 and incubated for 21 days at 37°C. Medium was changed every 4 days.

Adipogenic differentiation was induced by culturing in DMEM (high glucose) medium with 20% FCS, 1 µM dexamethasone, 0.35 µM hydrocortisone, 0.5 mM isobutyl-methylxanthine (IBMX), 100 ng/ml insulin, and 60 µM indomethacin. Cells were seeded at 20,000 cells/cm2 and incubated for 12 days at 37°C. Medium was changed every 4 days.

Chondrogenic differentiation was obtained in micropellets (3 x 105 cells/pellet) incubated at 37°C for 21 days in 500 µl of chondrogenic medium composed of DMEM (high glucose) with 0.1 µM dexamethasone, 1 mM sodium pyruvate, 170 µM ascorbic acid-2-phosphate, 350 µM proline, 1x insulin-transferrin-selenium, and 10 ng/ml transforming growth factor (TGF)-ß1. Medium was changed every 4 days. RNA studies required the use of 20–30 micropellets.

Vascular smooth muscle differentiation was obtained in long-term culture medium: McCoy's 5A medium with 12.5% screened horse serum, 12.5% FCS, 20 µM L-glutamine, 0.8 mM L-serine, 0.15 mM L-asparagine, 1 mM sodium pyruvate, 5 mM sodium bicarbonate, 1 µM hydrocortisone, and antimycotics and antibiotics. Cells were passaged at the end of the first week; during the two remaining weeks, medium was changed every 4 days.

Cytochemical staining.
Alkaline phosphatase was evaluated, after 4 and 15 days of culture in osteogenic medium, with the Alkaline Phosphatase Substrate Kit (Bio-Rad), added directly to the cell layer for 20 min at room temperature. For evaluation of the mineralized matrix, the cell layer was fixed with 4% (vol/vol) formaldehyde, then stained by von Kossa's stain using 5% (wt/vol) silver nitrate (Sigma) under ultraviolet light for 45 min, followed by 5% (wt/vol) sodium thiosulphate (Sigma) for 2 min: areas of mineralization were evaluated with LUCIA software (Nikon). For Nile O Red staining (NRO), cells were fixed with 4% formaldehyde and stained with 1 µg/ml Nile-red-O (Sigma) for 30 min. For safranin O staining, micropellets were fixed with 4% formaldehyde for 24 h and then embedded in paraffin. Slides were stained with 0.1% (wt/vol) safranin O (Sigma) for 5 min and counterstained with 0.02% (wt/vol) Fast Green for 3 min.

Immunofluorescence.
Cells were cultured on Lab-Tek chamber slides (Nunc). Confluent layers were fixed and permeabilized with methanol for 10 min. Slides were incubated for 1 h with mouse anti-human smooth muscle myosin heavy chains (hSMV, Sigma), followed by Alexa-488-conjugated goat anti-mouse antibody (Interchim), for 30 min. After staining, slides were mounted with Vectashield + DAPI (Vector) and examined with a Leica DMR microscope (Leica Microsystems).

RT-PCR.
Total RNA was extracted using the RNeasy Tissue Kit (Qiagen) according to the manufacturer's instructions. RNA concentration was determined by spectrophotometry at 260 nm, and RNA integrity was evaluated by electrophoresis of 2 µg of total RNA in 1% (wt/vol) agarose and 1x Tris-acetate/EDTA. RT-PCR was performed on 10 ng of total RNA using the SuperScript One-Step RT-PCR System with Platinum (Invitrogen) and Applied Biosystems PCRsystem 2700. Primer sequences are as follows (F, forward; R, reverse): Gapdh (F: ggtgaaggtcggtgtgaacg; R: catcatacttggcaggtttctcc; 55°C, 761 bp); Acta2 (F: gctgttttcccatccatcgtg; R: tggtgatgatgccgtgttctatc; 56.2°C, 148 bp); Agc1 (F: tcctctccggtggcaaagaagttg; R: ccaagttccagggtcactgttaccg; 55°C, 270 bp); Bglap1 (F: ctgagtctgacaaagccttc; R: gctgtgacatccatacttgc; 60°C, 313 bp); Des (F: cagatgagggagctggaggatc; R: tgggtgtgatatccgagagtgg; 56.1°C, 449 bp); Fabp4 (F: ctcctcctcgaaggtttacaaaatg; R: cctttcataacacattccaccacc; 56°C, 387 bp); Lpl (F: tgtaactgttctgccctcccc; R: ttctctcttgacagggcggc; 55°C, 456 bp); Pparg (F: tcggaatcagctctgtggacc; R: aacagcttctccttctcggcc; 56°C, 538 bp). For real-time quantitative RT-PCR, reverse transcription was performed using the HighCapacity cDNA Archive Kit (Applied Biosystems) on 3 µg of total RNA; PCR was then performed using the Taqman-Low-Density Arrays Microfluidic Cards (Applied Biosystems), according to the manufacturer's instructions.

Western blotting.
For Western blotting, described in detail in Ref. 9, primary antibodies were mouse anti-human monoclonal antibodies (mAbs) from Sigma-Aldrich that are cross-reactive with mouse proteins: anti-vinculin (Vin11-5), anti-caldesmon (hCald), and anti-smooth muscle myosin heavy chains (hSMV). Secondary antibody was goat anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad). Revelation by chemiluminescence was performed by ECLplus Western Blotting Detection Kit (Amersham Biosciences) and acquisition with Chemi-Smart 2000 using Chemocapt software (Vilbert-Lourmat).

Flow cytometry.
Cells were detached using phosphate-buffered saline (PBS) with 1 mM EDTA. Primary antibodies were purified rat anti-mouse mAbs from BD Biosciences: CD34 (RAM34), CD44 (IM-7), CD45 (30F-11), CD49d (R1-2AKR), CD49e (5H10-27), CD105 (MJ7/18), CD106 (429), and Sca-1 (D7) or their negative controls (rat IgG1, IgG2a, and IgG2b). Secondary antibody was phycoerythrin (PE)-conjugated goat anti-rat antibody. Cells were passed through a FACSCalibur flow cytometer (Becton-Dickinson) using a 488-nm argon laser. Samples were analyzed by collecting 10,000 events using Cell-Quest software (Becton-Dickinson).

Hematopoiesis Supportive (Stromal) Capacity
Cobblestone area-forming cell.
The hematopoietic population of precursors was purified from 4- to 6-wk-old C57Bl/6J mouse cells. Sca1+/Lin cells were isolated following, first, depletion of lineage-positive cells using a lineage cell depletion kit (Miltenyi) and, second, isolation of Sca1+ cells with a PE selection kit (EasySep) using anti-Sca1 antibody conjugated to PE (D7, BD Biosciences). The protocol for the study was submitted to and approved by the local Ethical Committeee. The purity was >95%, as evaluated by flow cytometry. Sca1+/Lin cells were plated on irradiated (15Gy) confluent layers of AFT024 or BMC9 grown on 96-well plates, using 6–24 replicas of 7 cell concentrations (1–200 cells/well). Cobblestone area-forming cell (CAFC) frequency was determined by limit-dilution analysis using Poisson statistics.

Flow cytometry.
Analysis of hematopoietic precursors co-cultivated for 5 wk with the stromal layers was carried out using flow cytometry. Cells were labeled with rat anti-mouse mAbs from BD Biosciences: anti-CD45 (30-F11) conjugated to allophycocyanin (APC), anti-Sca-1 (D7) conjugated to PE, and antibodies conjugated to FITC, either CD4 (GK1.5) + CD8a (53-6.7) + CD45R (B220), or CD11b (M1/70), CD51 (RMV-7), CD14 (55-3), and Ter119 (Ter-119).

Gene Screening by CEA Chip
The mouse CEA chip consists of 13,060 cDNA clones from early mouse embryo libraries constructed by the National Institute on Aging (NIA; http://www.nia.nih.gov) representing ~11,000 genes. It also includes positive [actin, tubulin, oligo(dT), cot-1 DNA] and negative (Tris-EDTA/DMSO) controls present many times in the array for quality control. Microarrays were prepared by spotting PCR products as previously described. The DNA chip used for this experiment is described and available at Gene Expression Omnibus (GEO; GPL3438 and GPL3439).

RNA extraction.
For each line, RNA was extracted from two independent cultures. Total RNA was isolated using the Trizol reagent (Invitrogen) and dissolved in RNase-free water. The quality of RNA was controlled using an Agilent 2100 Bioanalyzer (Agilent Technologies), and concentration was measured by absorbance at 260 nm. For each target preparation, 20 µg of total RNA were reverse transcribed using Superscript II RT (Life Technologies) in the presence of an oligo(dT)-primed reaction and an amino-modified nucleotide (amino-allyl-dUTP). Amino-modified cDNAs were purified through a Microcon Centricon 30 microconcentrator (Amicon) and ethanol precipitated. In a second step, monofunctional forms of Cy3 and Cy5 dyes (Amersham Biosciences) were coupled with the purified amino-modified cDNAs. Unincorporated fluorescent molecules and salts were removed through the Microcon Centricon 30. Labeled cDNA was mixed with 10 µg of poly(A) RNA (Boehringer), 10 µg of tRNA (Life Technologies), and 10 µg of mouse Cot1 DNA (Life Technologies). Purified labeled targets were hybridized to the array overnight as previously described (3). The cell lines 2018, BFC012, and BMC9 were each compared with AFT024. Each comparison was performed four times in both labeling orientations (8 hybridizations per comparison, 4 dye swaps).

Microarray data processing.
Fluorescence intensities of Cy3 and Cy5 were measured separately at 532 and 635 nm, respectively, with a laser scanner (Axon GenePix 4000A). Image analysis was performed with GenePix Pro 4.0 software (Axon). Spots with obvious blemishes were flagged. Genes with null intensity values and low mean intensity were also annotated with a specific flag and excluded from the list of validated differentially expressed genes. Statistical analysis of experimental data was performed after an intensity-dependent LOWESS normalization (47) with BioConductor/Limma (version 1.8.16) (39), using a standard ANOVA performed on the logarithm of gene expression data without background subtraction as described in Ref. 12. We did not apply a threshold on the ratio values of gene expression but instead used the t-test to determine significance as such: results significantly different from 1 (P value < 0.05) were determined from the eight values obtained for each comparison. The microarray data set used for this analysis is described and available from GEO (GSE4491).

Gene network analysis.
The interactions between genes identified as differentially expressed and all other genes were investigated using the Ingenuity Pathways Analysis (IPA). A series of networks was generated; a network is defined by IPA as the reflection of all interactions of a given protein defined in the literature. The interaction indicates physical association or consists of induction/activation or repression/inactivation/degradation of one gene product by the other, eventually through another intermediary molecule (indirect interaction). The program calculates a statistical score based on a right-tailed Fisher's exact test that calculates the fit of each network to the set of studied genes. A score >2 indicates that there is a less than 1 in 100 chance that the studied genes are assembled into the network because of random chance. We considered only the networks with the highest scores (>50). We introduced in the analysis two sets: that of upregulated genes and that of downregulated genes. The two major networks for up- and downregulated genes were then compared to find out the interactions among genes belonging to either network.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Previous studies have shown that the four 14.5 dpc fetal liver lines (AFT024, 2012, 2018, and BFC012) varied greatly in their ability to support hematopoiesis, with AFT024 being the best supporter (18). The mesenchymal differentiation potential of the fetal liver lines was not evaluated in previous works. On the contrary, in another report, the adult bone marrow line BMC9 was shown to be tripotent (with A, O, and C differentiation potential) and supportive for osteoclasts, while BMC10 was deficient in both A differentiation and osteoclast support (14).

AFT024 and BMC9 Are Quadripotent Mesenchymal Lines
After 12 days in adipogenic medium, many AFT024 and BMC9 cells contained large (~5 µm in diameter) NRO+ vesicles (Fig. 1A), and adipocytic markers (Fig. 2A) were induced (lipoprotein lipase; Lpl) or increased [fatty acid-binding protein (Fabp4) and peroxisome proliferator-activated receptor-{gamma} (Pparg)]. After 21 days in osteogenic medium, many von Kossa+ mineralized areas were apparent (Fig. 1A), and for AFT024, the osteocalcin (Bglap) osteoblastic marker was increased (Fig. 2A). Alkaline phosphatase was significantly increased in both lines at day 4 (P < 0.05) and day 15 (P < 0.001) (Fig. 2B). After 21 days in chondrogenic culture conditions, safranin O+ well-formed micropellets were apparent (Fig. 1A), and the aggrecan-1 (Agc1) chondrocytic marker was clearly induced in both lines (Fig. 2A). After 21 days of cells being in long-term culture medium inducing V differentiation, immunofluorescence studies indicated the presence of microfilaments containing smooth muscle myosin in most AFT024 cells and about one-half of BMC9 cells (Fig. 1B). {alpha}-Smooth muscle actin (Acta2) transcripts in AFT024 and desmin (Des) transcripts in both lines were slightly increased (Fig. 2A). Western blotting studies indicated that the smooth muscle myosin heavy chain SM1 was enhanced in AFT024, h-caldesmon was clearly induced in both lines, and metavinculin was detected in both (Fig. 2C). Finally, all cells from both lines expressed, at high a level, CD106, Sca-1, and CD49e; on the other hand, there was no expression of CD45, CD34, CD49d, and CD90 (not shown).


Figure 1
View larger version (83K):
[in this window]
[in a new window]

 
Fig. 1. Differentiation potential of the cell lines, cellular markers. A: histochemistry (all lines, 1 representative experiment of 3). The following is presented for each line: morphology (phase contrast) of cells cultured in proliferation medium, staining by von Kossa stain after 21 days in osteogenic medium, staining by Nile Red O after 12 days in adipogenic medium, and staining by safranin O on micropellets maintained for 21 days in chondrogenic medium. Bar = 100 µm. B: immunofluorescence for AFT024 and BMC9 cells stained with anti-smooth muscle (SM) myosin; for vascular smooth muscle cell (V) differentiation, cells were cultured for 21 days in the long-term culture medium, before fixation and staining.

 

Figure 2
View larger version (44K):
[in this window]
[in a new window]

 
Fig. 2. Differentiation stromal potential of the cell lines, molecular markers. A: RT-PCR. Expression of differentiation-specific transcripts for adipocytes (Lpl, Fabp4, and Pprag), osteoblasts (Bglap), chondrocytes (Agc1), and vascular smooth muscle cells (Des and Acta2). Housekeeping gene = Gapdh. Before extraction, cells were cultured in respective media as indicated in Fig. 1. C, control medium; I, induction medium. B: alkaline phosphatase concentration as expressed by the ratio of day 4 to day 0 and day 15 to day 0. Statistical significance (8 experiments per time point for each line) was evaluated using ANOVA: *P < 0.05 and **P < 0.01. C: Western blotting. Expression of vascular smooth muscle-specific proteins showing the induction or not of the 200-kDa smooth muscle myosin heavy chain (SM1), of h-caldesmon (h-Cald), and of metavinculin (MetaVcl). ß-Act, ß-actin.

 
In 2012 and BMC10 cells, after A differentiation, most NRO+ vesicles (Fig. 1A) were of small size, and Fabp4 and Pparg were enhanced, while Lpl was not detected in BMC10 (Fig. 1B). After O differentiation, many von Kossa+ mineralized areas were apparent (Fig. 1A), and Bglap was increased (Fig. 2A). Alkaline phosphatase was significantly increased at day 4 (P < 0.001) in 2012 and day 15 (P < 0.001) in both lines (Fig. 2B). After C differentiation, micropellets contained few safranin O+ areas (Fig. 1A). After V differentiation, Acta2 and Des transcripts remained unchanged (but the band was faint in 2012) (Fig. 2A); h-caldesmon, SM1, and metavinculin were increased in 2012, but h-caldesmon and SM1 remained barely detectable in BMC10 (Fig. 2C). The immune phenotype was as described for AFT024 and BMC9 (not shown).

In 2018 and BFC012, after A differentiation, few cells with small-sized NRO+ vesicles were detected (Fig. 1A); in 2018, but not BFC012, Lpl, Fabp4, and Pparg were induced (Fig. 2A). After O differentiation, von Kossa+ mineralized areas were not detected in either lines (Fig. 1A), but in 2018, Bglap was detected before differentiation and unchanged after (Fig. 2A). Alkaline phosphatase was significantly increased at day 4 (P < 0.001) in 2018 and day 15 (P < 0.001) in both lines (Fig. 2B), which suggested that both lines were able to differentiate, more or less readily, into O but were defective for mineralization. After C differentiation, micropellets contained no safranin O+ areas (Fig. 1A), and Agc1 induction was weak in BFC012 (Fig. 2A). After V differentiation, Des transcripts were induced in 2018, but barely in BFC012, and Acta2 was unchanged (Fig. 2A); a faint h-caldesmon band was apparent, but no metavinculin, while SM1 was unchanged in BFC012 (Fig. 2C). CD49e expression was low in both lines; Sca-1 was not detected in BFC012, and CD34 was expressed in both lines (not shown).

In conclusion, AFT024 and BMC9 were clearly quadripotent and showed an immune phenotype of murine MSCs. All other lines showed impaired differentiation at one or several levels. The lines with the most impaired differentiation potential were 2018 and BFC012; these lines also showed unusual expression of some of the membrane markers.

AFT024 and BMC9 Are Stromal Lines
The hematopoietic supportive ability was studied in both lines by seeding irradiated cells with bone marrow mouse Sca1+/Lin cells (Fig. 3). The CAFC frequency (Fig. 3, C and D) from two HSC enrichments after 5 wk was 1/40–1/50 and 1/110–1/160 for AFT024 and BCM9, respectively. Flow cytometry studies (Fig. 3B) indicated the persistence of immature Sca1+/CD45+ hematopoietic cells along with more mature CD11b+/CD45+ granulocytes, CD14+/CD45+ monocytes, and CD51+/CD45+ megakaryocytes, without significant difference between the two cell lines. Very few TER119+/CD45+ erythroid cells were detected on BMC9. CD4+/CD45+, CD8+/CD45+, or CD45R+/CD45+ lymphoid cells were not detected. The presence of megakaryocytes, polymorphs, and monocytes was confirmed by cytology after May Grunwald Giemsa staining (Fig. 3A). In conclusion, both lines displayed hematopoietic support, with an advantage for AFT024 in terms of CAFC frequency.


Figure 3
View larger version (43K):
[in this window]
[in a new window]

 
Fig. 3. Stromal potential of AFT024 and BMC9. A: cytology of hematopoietic cells (Sca1+/Lin) cultured for 5 wk on either line, showing the presence of megakaryocytes, polymorphs, and monocytes. B: flow cytometry studies performed on hematopoietic cells cultured for 5 wk on either line. C: cobblestone area formation from hematopoietic cells after 5 wk in culture. D: cobblestone area-forming cell (CAFC) frequency as measured after 5 wk for hematopoietic cells cultured at limit dilution.

 
Molecular Profile of Stromal MSCs
Results from the above cellular studies indicated that AFT024 and BMC9 were adequate models for stromal multipotential MSCs, whereas 2018 and BFC012 with severely defective stromal and differentiation potential were negative control lines. To determine the molecular profile specific for stromal multipotential MSCs independent of the hematopoietic site, we ascertained the set of genes differentially expressed in the intersection set of AFT024 and BMC9 compared with those expressed in the union set of the two negative control lines 2018 and BFC012. The lines BMC10 and 2012, with partially defective differentiation and stromal potential, were not considered in the analysis. Our strategy was, first, to determine the set of genes included in the union of genes expressed by 2018 and BFC012 (U1 = 2018 {cup} BFC012); second, to subtract this union set from genes expressed by AFT024 (S1 = AFT024 – U1) and by BMC9 (S2 = BMC9 – U1); and, third, to determine the intersection of S1 and S2 (S3 = S1 {cap} S2). There were 346 upregulated and 299 downregulated genes in S3. Functional classification is shown in Fig. 4. Hierarchical clustering validated our strategy, the genes up- or downregulated in BMC9 (2 distinct extractions, 8 dye swaps) showing the greatest similarity to those in AFT024, whereas those in BFC012 showed the greatest dissimilarity (Fig. 5).


Figure 4
View larger version (24K):
[in this window]
[in a new window]

 
Fig. 4. Functional classification of genes up- and downregulated in mesenchymal stem cells (MSCs). This classification was performed after analysis of the data in the literature for each of the genes.

 

Figure 5
View larger version (82K):
[in this window]
[in a new window]

 
Fig. 5. Hierarchical clustering of genes up- and downregulated in MSCs. Each column indicates the level of gene expression in BMC9, 2018, and BFC012, as related to that in AFT024. Color scale indicates the degree of similarity. Gene clusters are shown at left and right sides (for upregulated and downregulated genes, respectively). The Sr-2 red box includes 11 genes present in the network of upregulated genes (shown in Fig. 6B).

 
Supplemental Table 1 (supplemental data are available at the online version of this article) gives the list of downregulated genes belonging to the following categories: cytoskeleton, transcription and chromatin remodeling, signaling, adhesion, trafficking, metabolism, cell cycle and apoptosis, protein synthesis and degradation, and other. Study of gene networks using Ingenuity software revealed a major network of 35 genes, with a highly significant score of 64 (Network 1, Fig. 6A). Ten of the downregulated genes in this network coded for proteins implicated positively in osteogenic differentiation, proliferation, or transformation: protooncogene protein c-fos (Fos), parathyroid hormone-related protein (Pthlh), adrenomedullin (Adm), receptor activity-modifying protein 2 (Ramp2), apoptosis regulator Bcl-2 (Bcl2), ezrin (Vil2), estrogen receptor 1 (Esr1), proline-rich nuclear receptor co-activator 1 (Pnrc1), guanine nucleotide-binding protein G, {alpha}-subunit (Gnas), and regulator of G protein signaling 2 (Rgs2).


View this table:
[in this window]
[in a new window]

 
Table 1. Stemness gene candidates

 

Figure 6
View larger version (34K):
[in this window]
[in a new window]

 
Fig. 6. Studies of gene networks up- and downregulated in MSCs. A: major network (Network 1) of genes downregulated in MSCs (as given by the Ingenuity software). The no. under each gene name indicates the mean log signal ratio for AFT024 – (2018 {cup} BCF012); similar values were obtained for BMC9 – (2018 {cup} BCF012). B: major network (Network 2) of genes upregulated in MSCs. A and B: regular line for physical association, arrow line for induction/activation, blunt-ended line for repression/inactivation/degradation, and discontinuous line for indirect interaction. Details about the interactions are given in Supplemental Table 4.

 
Supplemental Table 2 lists the upregulated genes grouped into the same categories as in Supplemental Table 1. Study of gene networks using the Ingenuity software revealed a major network of 35 genes, with a highly significant score of 56 (Network 2, Fig. 6B). Most interactions in this network were direct and consisted of physical association or induction. Transcripts belonged to two categories, transcripts for cytoskeletal molecules and transcripts implicated in the regulation of the transcriptional machinery (including chromatin remodeling). The genes of this network encoding proteins implicated in the cytoskeleton were as follows: the structural proteins tropomyosins (Tpm3, Tpm1), moesin (Msn), cytoplasmic 1 actin (Actb), cytoplasmic 2 actin (Actg1), the molecular chaperones for actin and tubulin, T-complex protein 1 subunit-{gamma} (Cct3), -{epsilon} (Cct5), and -{eta} (Cct7), and molecules involved in the regulation of microfilament or microtubule assembly/dynamics, rhophilin (Rhpn2), transforming protein RhoA (Rhoa), phospholipase D1 (Pld1), myosin regulatory light chain MRCL2 (Mrlc2), protein diaphanous homolog 3 (Diaph3), and ADP-ribosylation factor 1 (Arf1). Gene Ontology analysis confirmed the significance (P < 0.02 by Fisher's exact test) of the overrepresentation of biological processes, cellular components, and molecular functions involved in cytoskeletal organization. The complete list of upregulated genes (Supplemental Table 2) confirmed the presence of many cytoskeletal genes not included in the network described above. The molecules of the network involved in the regulation of transcription were as follows: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin (Smarcc1), the splicing factors heterogeneous nuclear ribonucleoprotein-A1 (Hnrpa1), -D0 (Hnrpd), -U (Hnrpu) and -K (Hnrpk), the arginine/serine-rich proteins 1 and 3 (Sfrs1, Sfrs3), ruvB-like 1 (Ruvbl1), actin-like protein 6A (Actl6a), putative RNA-binding protein 3 (Rbm3), GATA-binding protein 2 (Gata2), four and a half LIM domains protein 2 (Fhl2), zinc finger protein 638 (Znf638), high-mobility group nucleosome-binding domain-containing protein 2 (Hmgn2), protein flightless-1 homolog (Flii), and Cullin-1 (Cul1). Some of the cytoskeletal molecules are known to be associated to molecules involved in the transcription machinery: Rhoa is functionally associated to Fhl2, as activated Rhoa induces the translocation of Fhl2 to the nucleus and its subsequent activation (31); Actl6a, Ruvbl1, and Smarcc1 are part of molecular complexes associating transcriptional regulators to molecules of the cytoskeleton such as Actb (15, 34). Two transcripts, Fhl2 and Ruvbl1, are implicated in the Wnt signaling pathway, known to modulate the transcriptional transactivation of ß-catenin in association with LEF1/TEF factors (45).

Certain molecules of the network of downregulated genes (Network 1) are known to be physically associated to those of the network of upregulated genes (Network 2) (Fig. 6): villin 2 (Network 1) to moesin and cytoplasmic 1 actin (Network 2); and NF-{kappa}B inhibitor-{alpha} and Fos (Network 1) to different heterogeneous nuclear ribonucleoproteins and to cytoplasmic 2 actin, ADP-ribosylation factor 1, and RhoA (Network 2) (2, 10, 11, 17, 19, 22, 32, 44). Eleven (of 35) molecules of the network of upregulated genes were localized in a specific cluster, Sr-2, that contained 46 genes (Fig. 5).

The molecules included in the two networks and their interacting partners are listed in Supplemental Table 4.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Our study indicates that two mouse mesenchymal clonal lines, one from bone marrow (BMC9) and the other from fetal liver (AFT024), possess the characteristics of stromal MSCs. Both lines were able to differentiate into adipocytes, mineralizing osteoblasts, chondrocytes, and vascular smooth muscle cells and supported Sca1+/Lin mouse bone marrow hematopoietic precursors, allowing the generation of cobblestone areas and the differentiation of myeloid precursors. On the contrary, in the other lines, the mesenchymal differentiation potential was impaired at one or several levels. The differentiation defect was most severe in 2018 and BFC012. These lines gave rise to few adipocytes, did not generate mineralizing osteoblasts, gave, under chondrogenic condition, loose aggregates that were safranin O negative, and expressed, after V differentiation, low amounts of h-caldesmon. In addition, it has been shown in a previous study that none of these two lines allowed the maintenance of HSCs (18).

It has been suggested that the two populations, that of MSCs (isolated by their adherence to plastic and containing stem cells/progenitors for the A, O, C lineages) and that of stromal cells (used as feeder layers for long-term cultures of HSCs), are identical (37). This hypothesis has been sustained for culture-expanded bone marrow primary human MSCs (28). Our study extends this concept of stromal MSCs to clonal cell populations derived not only from bone marrow but also from fetal liver.

To determine the transcriptomic profile specific for stromal multipotential MSCs independent of the hematopoietic site, we ascertained the set of genes differentially expressed in the intersection set of AFT024 and BMC9 compared with those expressed in the union set of the two negative control lines, 2018 and BFC012. We found that 645 transcripts were specifically regulated in the two stromal multipotential cell lines, with a similar number of up- and downregulated genes.

Some of the upregulated transcripts appeared to be of special interest and already have been described in the literature on stromal cells: the serine/threonine kinase NLK (Nlk) and the Jumonji protein 1a and 2 (Jarid1a, Jarid2), because of their demonstrated role as stromal mediator and differentiating factor for stromal cells (23, 25), and the lymphocyte-specific adapter protein Lnk (Lnk), because of its implication in the interaction between HSCs and cells from the microenvironment (41).

As shown in Table 1, 42 transcripts in our set of upregulated genes were also found upregulated in other embryonic or adult hematopoietic or neural stem cells (4, 21, 27, 33, 38, 42, 43, 49). Such transcripts may be characteristic of the stem cell state (50). Studies using short interfering RNA (20, 40) should confirm this hypothesis.

Because our gene chip encompasses about only one-third of the known mammalian genome, the number of up- and downregulated genes might be larger than what is described here. In particular, some categories found in other genetic screens as implicated in stromal support (8) are insufficiently represented in the chip used here (especially proteoglycans and chemokines).

We chose to study specific clones that were immortalized using a temperature-sensitive SV-40 T-antigen for the following reasons. 1) These clones have been studied in detail previously (14, 18), either for their stromal capacity (fetal liver lines) or for their differentiation potential (bone marrow lines). 2) The introduction of the viral sequence would insure sufficient proliferation, in particular when studying chondrogenic differentiation using the micropellet technique, requiring large cell numbers. 3) Mouse cells immortalized by T show a phenotype comparable to nontransduced cells (9).

To assess the potential influence of viral genes on the expression of cell genes, we have recently compared, using microfluidic cards from Applied Biosystems, the expression of 380 transcripts in clones derived from primary cultures of mouse bone marrow MSCs vs. BMC9 and BMC10. We have found that 7% of the transcripts were up- or downregulated in cells with large T. The studied transcripts belonged to several categories. The least affected category was that of cytoskeletal components (only 3% of the genes in this category were significantly modulated). On the other hand, the most affected category was that of molecules involved in cell cycle and apoptosis: 39% of the studied cyclins, cyclin inhibitors, and apoptosis inhibitors were upregulated in BMC9 and BMC10. Molecules implicated in the transcriptional machinery were only marginally affected (6%). These data indicate that the expression of genes belonging to the cell cycle and apoptosis category (see Supplemental Tables 1 and 2) may have been influenced by the viral sequence insertion. However, most genes present in the networks (vide below) are probably minimally influenced by the presence of T.

Using the Ingenuity software, we found two major networks with highly significant scores >50. The network of 35 downregulated genes contained 10 transcripts positively implicated in osteoblastic differentiation, proliferation, or transformation. These data suggest that the intersection set of AFT024 and BMC9 is representative of bona fide undifferentiated cells, in contrast to the set of 2018 and BFC012, which appears to represent cells already committed to the osteogenic pathway albeit unable to complete it by mineralization when placed in an osteogenic condition.

The network of 35 upregulated genes belonged to two categories, transcripts for cytoskeletal molecules and transcripts implicated in the regulation of the transcriptional machinery (including chromatin remodeling). Cytoskeletal molecules included structural components of actin-based cytoskeleton, chaperones for actins and tubulins, and proteins involved in the signaling pathways leading to the assembly/disassembly of microtubules and microfilaments. Some of the molecules implicated in the transcriptional machinery have been detected in protein complexes associated with cytoskeletal components, such as the NuA4 histone acetylase complex (15) or the BAF53 complex (34).

Networks have not been emphasized in previous transcriptomic studies on stem cells (4, 21, 27, 33, 35, 38, 40, 42, 43, 46, 49). The networks described in the present study may serve as a basis for future experiments. First, one may assess whether the same networks are found in MSCs from primary cultures (polyclonal and clonal cultures). Second, one may investigate whether the hyperexpression of some of the network cytoskeletal components (either structural, such as moesin or cytoplasmic actin 1, or regulatory, such as RhoA) induces the hyperexpression or downregulation of some of the molecules implicated in the transcription machinery and in the differentiation pathways. As a final point, it will be essential to verify whether the hyperexpression of a cytoskeletal component belonging to the gene network of upregulated molecules improves or hampers the differentiation and/or stromal potentials of the transduced cells. Genetic regulatory networks provide essential information on the generation of the different cell types (26). Future experiments should indicate whether the gene networks presently described are genetic regulatory networks (i.e., include molecules involved in positive or negative regulatory loops) that determine the maintenance in a nondifferentiated state of this particular stem cell type.

In conclusion, this study describes gene networks for stromal MSCs from the two major hematopoietic sites that should help discriminate this cell type from other stem cells (ES, neural, hematopoietic, etc.) and help define the stem cell state.


    GRANTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by grants from the European Union (Integrated Project "Genostem" no. 503161), from Fondation de France (no. 2002002384), from Association de Recherche sur le Cancer (no. 5827), from Electricité de France, and from the National Heart, Lung, and Blood Institute (NIH-HL-58739). S. Chateauvieux was supported in part by the Société Française d'Hématologie.


    ACKNOWLEDGMENTS
 
We thank Jorge Domenech, Olivier Hérault, and Cyrille Petat for helpful discussion on different methodological aspects of this work.


    FOOTNOTES
 
Address for reprint requests and other correspondence: P. Charbord, Laboratoire d'Hématopoièse, Faculté de médecine, bâtiment Dutrochet, 10 Bvd Tonnellé, Tours 37032, France (e-mail: charbord{at}med.univ-tours.fr).

Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immun 7: 333–337, 2006.[CrossRef][Web of Science]
  2. Adilakshmi T, Laine RO. Ribosomal protein S25 mRNA partners with MTF-1 and La to provide a p53-mediated mechanism for survival or death. J Biol Chem 277: 4147–4151, 2002.[Abstract/Free Full Text]
  3. Benchaouir R, Rameau P, Decraene C, Dreyfus P, Israeli D, Pietu G, Danos O, Garcia L. Evidence for a resident subset of cells with SP phenotype in the C2C12 myogenic line: a tool to explore muscle stem cell biology. Exp Cell Res 294: 254–268, 2004.[CrossRef][Web of Science][Medline]
  4. Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, Yang AX, Joshi BH, Ginis I, Thies RS, Amit M, Lyons I, Condie BG, Itskovitz-Eldor J, Rao MS, Puri RK. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood 103: 2956–2964, 2004.[Abstract/Free Full Text]
  5. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 105: 1663–1668, 2000.[Web of Science][Medline]
  6. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98: 2396–2402, 2001.[Abstract/Free Full Text]
  7. Chagraoui J, Lepage-Noll A, Anjo A, Uzan G, Charbord P. Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood 101: 2973–2982, 2003.[Abstract/Free Full Text]
  8. Charbord P, Moore K. Gene expression in stem cell-supporting stromal cell lines. Ann NY Acad Sci 1044: 159–167, 2005.[CrossRef][Web of Science][Medline]
  9. Charbord P, Oostendorp R, Pang W, Herault O, Noel F, Tsuji T, Dzierzak E, Peault B. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissues. Exp Hematol 30: 1202–1210, 2002.[CrossRef][Web of Science][Medline]
  10. Chen CY, Xu N, Shyu AB. Highly selective actions of HuR in antagonizing AU-rich element-mediated mRNA destabilization. Mol Cell Biol 22: 7268–7278, 2002.[Abstract/Free Full Text]
  11. Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, Bauskin A, Mercurio F, Mann M, Ben-Neriah Y. Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNP-U. Genes Dev 16: 439–451, 2002.[Abstract/Free Full Text]
  12. Decraene C, Benchaouir R, Dillies MA, Israeli D, Bortoli S, Rochon C, Rameau P, Pitaval A, Tronik-Le Roux D, Danos O, Gidrol X, Garcia L, Pietu G. Global transcriptional characterization of SP and MP cells from the myogenic C2C12 cell line: effect of FGF6. Physiol Genomics 23: 132–149, 2005.[Abstract/Free Full Text]
  13. Dennis JE, Charbord P. Origin and differentiation of human and murine stroma. Stem Cells 20: 205–214, 2002.[CrossRef][Web of Science][Medline]
  14. Dennis JE, Merriam A, Awadallah A, Yoo JU, Johnstone B, Caplan AI. A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res 14: 700–709, 1999.[CrossRef][Web of Science][Medline]
  15. Doyon Y, Cote J. The highly conserved and multifunctional NuA4 HAT complex. Curr Opin Genet Dev 14: 147–154, 2004.[CrossRef][Web of Science][Medline]
  16. Dzierzak E, Oostendorp R. Hematopoietic stem cell development in mammals. In: Hematopoiesis. A Developmental Approach. Oxford, UK: Oxford Univ. Press, 2001, p. 209–217.
  17. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 17: 1331–1342, 1998.[CrossRef][Web of Science][Medline]
  18. Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci USA 99: 13061–13066, 2002.[Abstract/Free Full Text]
  19. Hay DC, Kemp GD, Dargemont C, Hay RT. Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription. Mol Cell Biol 21: 3482–3490, 2001.[Abstract/Free Full Text]
  20. Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR. Dissecting self-renewal in stem cells with RNA interference. Nature 442: 533–538, 2006.[CrossRef][Medline]
  21. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 298: 601–604, 2002.[Abstract/Free Full Text]
  22. Johnston IM, Spence HJ, Winnie JN, McGarry L, Vass JK, Meagher L, Stapleton G, Ozanne BW. Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion. Oncogene 19: 5348–5358, 2000.[CrossRef][Web of Science][Medline]
  23. Kitajima K, Kojima M, Nakajima K, Kondo S, Hara T, Miyajima A, Takeuchi T. Definitive but not primitive hematopoiesis is impaired in jumonji mutant mice. Blood 93: 87–95, 1999.[Abstract/Free Full Text]
  24. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology Bethesda 20: 349–356, 2005.[CrossRef][Medline]
  25. Kortenjann M, Nehls M, Smith AJ, Carsetti R, Schuler J, Kohler G, Boehm T. Abnormal bone marrow stroma in mice deficient for nemo-like kinase, Nlk. Eur J Immunol 31: 3580–3587, 2001.[CrossRef][Web of Science][Medline]
  26. Loose M, Patient R. Global genetic regulatory networks controlling hematopoietic cell fates. Curr Opin Hematol 13: 229–236, 2006.[Web of Science][Medline]
  27. Ma X, Husain T, Peng H, Lin S, Mironenko O, Maun N, Johnson S, Tuck D, Berliner N, Krause DS, Perkins AS. Development of a murine hematopoietic progenitor complementary DNA microarray using a subtracted complementary DNA library. Blood 100: 833–844, 2002.[Abstract/Free Full Text]
  28. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9: 841–848, 2000.[CrossRef][Web of Science][Medline]
  29. Mendes SC, Robin C, Dzierzak E. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 132: 1127–1136, 2005.[Abstract/Free Full Text]
  30. Moore KA, Lemischka IR. Stem cells and their niches. Science 311: 1880–1885, 2006.[Abstract/Free Full Text]
  31. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, Schule R. The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21: 736–748, 2002.[CrossRef][Web of Science][Medline]
  32. Ostrowski J, Kawata Y, Schullery DS, Denisenko ON, Higaki Y, Abrass CK, Bomsztyk K. Insulin alters heterogeneous nuclear ribonucleoprotein K protein binding to DNA and RNA. Proc Natl Acad Sci USA 98: 9044–9049, 2001.[Abstract/Free Full Text]
  33. Park IK, He Y, Lin F, Laerum OD, Tian Q, Bumgarner R, Klug CA, Li K, Kuhr C, Doyle MJ, Xie T, Schummer M, Sun Y, Goldsmith A, Clarke MF, Weissman IL, Hood L, Li L. Differential gene expression profiling of adult murine hematopoietic stem cells. Blood 99: 488–498, 2002.[Abstract/Free Full Text]
  34. Park J, Wood MA, Cole MD. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol Cell Biol 22: 1307–1316, 2002.[Abstract/Free Full Text]
  35. Phinney DG, Hill K, Michelson C, DuTreil M, Hughes C, Humphries S, Wilkinson R, Baddoo M, Bayly E. Biological activities encoded by the murine mesenchymal stem cell transcriptome provide a basis for their developmental potential and broad therapeutic efficacy. Stem Cells 24: 186–198, 2006.[CrossRef][Web of Science][Medline]
  36. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147, 1999.[Abstract/Free Full Text]
  37. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71–74, 1997.[Abstract/Free Full Text]
  38. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 298: 597–600, 2002.[Abstract/Free Full Text]
  39. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3, 2004.
  40. Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 24: 1707–1718, 2006.[CrossRef][Web of Science][Medline]
  41. Takizawa H, Kubo-Akashi C, Nobuhisa I, Kwon SM, Iseki M, Taga T, Takatsu K, Takaki S. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk. Blood 107: 2968–2975, 2006.[Abstract/Free Full Text]
  42. Terskikh AV, Easterday MC, Li L, Hood L, Kornblum HI, Geschwind DH, Weissman IL. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs. Proc Natl Acad Sci USA 98: 7934–7939, 2001.[Abstract/Free Full Text]
  43. Terskikh AV, Miyamoto T, Chang C, Diatchenko L, Weissman IL. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 102: 94–101, 2003.[Abstract/Free Full Text]
  44. Tsukita S, Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 274: 34507–34510, 1999.[Free Full Text]
  45. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 278: 5188–5194, 2003.[Abstract/Free Full Text]
  46. Wieczorek G, Steinhoff C, Schulz R, Scheller M, Vingron M, Ropers HH, Nuber UA. Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis. Cell Tissue Res 311: 227–237, 2003.[CrossRef][Web of Science][Medline]
  47. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15, 2002.[Abstract/Free Full Text]
  48. Yin T, Li L. The stem cell niches in bone. J Clin Invest 116: 1195–1201, 2006.[CrossRef][Web of Science][Medline]
  49. Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of gene expression in human CD34(+) stem/progenitor cells. Proc Natl Acad Sci USA 98: 13966–13971, 2001.[Abstract/Free Full Text]
  50. Zipori D. The stem state: plasticity is essential, whereas self-renewal and hierarchy are optional. Stem Cells 23: 719–726, 2005.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
GutHome page
H Aurich, M Sgodda, P Kaltwasser, M Vetter, A Weise, T Liehr, M Brulport, J G Hengstler, M M Dollinger, W E Fleig, et al.
Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo
Gut, April 1, 2009; 58(4): 570 - 581.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Durand, C. Robin, K. Bollerot, M. H. Baron, K. Ottersbach, and E. Dzierzak
Embryonic stromal clones reveal developmental regulators of definitive hematopoietic stem cells
PNAS, December 26, 2007; 104(52): 20838 - 20843.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. Kumar and S. Ponnazhagan
Bone homing of mesenchymal stem cells by ectopic {alpha}4 integrin expression
FASEB J, December 1, 2007; 21(14): 3917 - 3927.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
29/2/128    most recent
00197.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chateauvieux, S.
Right arrow Articles by Charbord, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chateauvieux, S.
Right arrow Articles by Charbord, P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.